by Joana Carvalho, PhD | Mar 8, 2021 | News
Adults with spinal muscular atrophy (SMA) usually do not experience weakness or impairment of any sort in the muscles controlling their eye movements, a recent study reported. When such impairments are present, they should prompt physicians to re-evaluate their...
by Joana Carvalho, PhD | May 28, 2020 | Just Published, News, Nursing News, Nursing Resource Pages, Pediatricians News, Pediatricians Resources, Physical Therapists News, Pulmonologist News, Pulmonologist Resource Pages, slider
Lung function in people with earlier-onset forms of spinal muscular atrophy (SMA) tends to decline gradually throughout childhood and stabilizes in early adulthood, according to data from a population-based natural history study. The study, “Natural history of lung...
by Joana Carvalho, PhD | May 20, 2020 | Neurology News, News, Nursing News, Orthopedics News, Pediatricians News, Physical Therapists News, Pulmonologist News, Radiology News, slider, Social Worker News
Although a disease of motor neurons, nerve cells of the spinal cord and brainstem, the earliest signs of spinal and bulbar muscular atrophy (SBMA) are in skeletal muscles, according to data from a mouse study. These findings suggest that changes in muscle strength and...
by Joana Carvalho, PhD | Apr 30, 2020 | Neurology News, News, Nursing News, Orthopedics News, Physical Therapists News, Pulmonologist News, slider
Spinal fusion surgery — a procedure to fuse two or more spine vertebrae — is more successful at reducing spine curvature in children with spinal muscular atrophy (SMA) type 1 and 2 if they have previously been given growth-friendly spinal implants, a study reports....
by Joana Carvalho, PhD | Apr 6, 2020 | Neurology News, News, Nursing News, Orthopedics News, Pediatricians News, Physical Therapists News, Pulmonologist News, Radiology News, Social Worker News, Urologists News
Young children given a single injection of Zolgensma into the spinal canal continue to show gains in motor function and safety, new interim data from the STRONG trial in spinal muscular atrophy (SMA) type 2 patients up to age 5 show. These findings from the open-label...